IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma
Cellectis presented promising data with UCART20x22, which represents a pioneering allogeneic dual CAR T-cell product designed to target two established antigens.
Theme > Industry > Healthcare > Immuno>Oncology
PD-1 inhibitors and systemic oncolytic viral immunotherapies under the spotlight at IO360
Immuno-oncology: the leading companies in oncolytic viruses revealed
Immuno-oncology: the leading companies in oncolytic adenovirus vectors revealed
Immuno-oncology: the leading companies in neoepitope prediction revealed
Leading innovators in PDK-1 inhibitors for the pharmaceutical industry
Immuno-oncology: the leading companies in cancer immunotherapy revealed
Immuno-oncology: the leading companies in immunotherapy radiotherapy combination revealed
